With the passage of the [[Drug Price Competition and Patent Term Restoration Act|Hatch-Waxman Act]] in 1984, Mylan and other small generic companies gained value; in the eighteen months following passage of the law Mylan's earnings grew 166% to $12.5 million and its stock value rose 800%.<ref>{{cite journal|last1=Lewis|first1=Ralph A.|title=The Emerging Effects of the Drug Price Competition and Patent Term Restoration Act of 1984|journal=Journal of Contemporary Health Law & Policy|date=1992|volume=8|issue=1|pages=361â€“378|url=http://scholarship.law.edu/cgi/viewcontent.cgi?article=1539&context=jchlp}}</ref>
